DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
1. DMAC to host KOL event on May 28, 2025, about preeclampsia treatment. 2. Experts will discuss DM199 and preeclampsia's current treatment landscape. 3. Preeclampsia affects up to 8% of pregnancies, with serious health risks. 4. DM199 could significantly improve maternal health outcomes in preeclampsia. 5. No approved therapies exist for preeclampsia, increasing DM199’s market potential.